Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

Cancer

Volumn 123, Issue 22, 2017, Pages 4403-4410

  Legros, Laurence ^a,b   Nicolini, Franck E ^c,d   Etienne, Gabriel ^e   Rousselot, Philippe ^f   Rea, Delphine ^g   Giraudier, Stéphane ^h   Guerci Bresler, Agnès ⁱ   Huguet, Françoise ^j   Gardembas, Martine ^k   Escoffre, Martine ^l   Ianotto, Jean Christophe ^m   Noël, Marie Pierre ⁿ   Varet, Bruno R ^o   Pagliardini, Thomas ^a   Touitou, Irit ^a   Morisset, Stéphane ^c   Mahon, Francois Xavier ^p  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITÉ DE LYON   (France)

^d CENTRE LÉON BÉRARD   (France)

^e INSTITUT BERGONIÉ   (France)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ CHU NANCY BRABOIS   (France)

^j University Institute of Cancer Oncopole   (France)

^k ANGERS UNIVERSITY HOSPITAL   (France)

^l RENNES UNIVERSITY HOSPITAL   (France)

^m BREST UNIVERSITY HOSPITAL   (France)

ⁿ LILLE UNIVERSITY HOSPITAL   (France)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p Bordeaux Institute of Oncology   (France)

more..

Author keywords

chronic myeloid leukemia; hematology; myeloproliferative disorders; therapy discontinuation; tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; MESSENGER RNA; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG RECHALLENGE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETREATMENT; TREATMENT DURATION; VERY ELDERLY; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; FRANCE; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FRANCE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 85026298358     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30885     Document Type: Article

References (28)

1. Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851-2857.
2. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58-60.
3. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-1035.
4. Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90:910-914.
5. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515-522.
6. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424-430.
7. Takahashi N, Kyo T, Maeda Y, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97:903-906.
8. Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer. 2013;49:3242-3246.
9. Lee SE, Choi SY, Bang JH, et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol. 2013;88:449-454.
10. Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528-e535.
11. Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846-854.
12. Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29:999-1003.
13. Mahon FX, Richter J, Guilhot J, et al. Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the Euro-Ski Trial [abstract]. Blood. 2016;128:787.
14. Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298-305.
15. Legros L, Rousselot P, Giraudier S, et al. Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response. Blood. 2012;120:1959-1960.
16. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809-1820.
17. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26:2172-2175.
18. Muller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22:96-102.
19. Flandrin-Gresta P, Cornillet P, Hayette S, et al. Recommendations for accreditation of laboratories in molecular biology of hematologic malignancies. Ann Biol Clin (Paris). 2015;73:595-630.
20. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363:2511-2521.
21. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17-23.
22. Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature. 2005;435:1267-1270.
23. Prost S, Relouzat F, Spentchian M, et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature. 2015;525:380-383.
24. Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010;24:1719-1724.
25. Ilander M, Olsson-Stromberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1109-1116.
26. Krause DS, Fulzele K, Catic A, et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med. 2013;19:1513-1517.
27. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood. 2009;114:1150-1157.
28. MacLean AL, Filippi S, Stumpf MP. The ecology in the hematopoietic stem cell niche determines the clinical outcome in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2014;111:3883-3888.